Лучшие больницы для «Hepatitis B Treatment» в Дубай, ОАЭ

The cost of Hepatitis B treatment varies considerably based on the required treatment modality. For outpatient antiviral management — which covers the comprehensive diagnostic workup (quantitative HBV DNA, FibroScan, liver function panel) plus a 3–6 month supply of first-line nucleos(t)ide analogue therapy — costs in India range from approximately USD 500 to USD 3,000. The equivalent workup and treatment programme in the UAE (Dubai or Abu Dhabi) typically costs USD 1,200 to USD 6,000. For patients requiring liver transplantation due to HBV-related end-stage liver disease or hepatocellular carcinoma within Milan criteria, living donor liver transplantation (LDLT) in India at a JCI- or NABH-accredited centre is priced in the range of USD 25,000 to USD 35,000 (inclusive of surgery, ICU, hospital stay of 14–21 days, post-transplant HBIG prophylaxis, and 30-day follow-up). The equivalent procedure at a JCI- and DHA-accredited centre in Dubai or Abu Dhabi typically costs USD 55,000 to USD 75,000. India is generally 45–60% more cost-effective than the UAE across all treatment tiers, while delivering comparable clinical outcomes through its large-volume transplant and hepatology programmes. Pegylated interferon-based treatment programmes (48-week course with monthly monitoring) are priced at approximately USD 1,800–USD 4,500 in India and USD 4,000–USD 9,000 in the UAE. All cost estimates provided through GAF Healthcare are all-inclusive and transparent, with no hidden charges.

The required in-country stay depends entirely on the treatment pathway prescribed. For patients commencing oral antiviral therapy (nucleos(t)ide analogues such as tenofovir alafenamide, tenofovir disoproxil fumarate, or entecavir), the initial in-country stay is typically 7–14 days. This allows time for the complete diagnostic workup (Days 1–3), specialist consultation and treatment initiation (Days 3–5), and a short observation period to confirm early tolerability and review any initial blood results. These patients are clinically stable and medically fit to fly following the initial monitoring period, with all subsequent follow-up managed via telemedicine. For patients undergoing a 48-week pegylated interferon programme, the first injection cycle and tolerability assessment takes approximately 2 weeks in-country; subsequent injections can be self-administered at home, with monthly virtual hepatologist check-ins. For liver transplant recipients, a minimum in-country stay of 6–8 weeks post-surgery is mandatory before international air travel is medically cleared. This ensures adequate wound healing, immunosuppression stabilisation (tacrolimus levels optimised), resolution of any early complications (bile leak, rejection episodes), and completion of the critical post-operative hepatitis B immunoglobulin (HBIG) induction protocol. Long-haul international flights expose transplant patients to risks of deep vein thrombosis and infection that are unacceptable before this timeline. Written fit-to-fly clearance is provided by the treating transplant surgeon and hepatologist before departure. GAF Healthcare assists with arranging extended serviced apartment stays at preferential rates for patients and their attendants during prolonged programmes.

Success rates for Hepatitis B treatment must be interpreted in the context of the specific treatment goal and modality, as 'success' is defined differently across the disease spectrum. For oral antiviral therapy (nucleos(t)ide analogues — TAF, TDF, or entecavir), virological suppression (HBV DNA <20 IU/mL) is achieved in 85–96% of treatment-naive patients within 48–96 weeks of consistent therapy. However, functional cure — defined as HBsAg loss with or without anti-HBs seroconversion, which represents the closest approximation to eradication achievable with current standard-of-care — occurs in only 1–3% of patients per year on NUC therapy alone. For pegylated interferon alfa-2a (48-week regimen), HBeAg seroconversion occurs in approximately 27–32% of HBeAg-positive patients, and HBsAg loss is achieved in 3–7% at end of treatment, rising to approximately 11% at 5-year follow-up — making it the preferred finite therapy for patients who are suitable candidates. With modern combination strategies (NUC + RNAi agents or CAMs in clinical trials), HBsAg loss rates of 20–40% at one year are being reported in investigational settings, representing a paradigm shift in treatment goals. For liver transplantation in HBV-related end-stage liver disease, 5-year patient survival rates at high-volume JCI-accredited centres in India and the UAE range from 80% to 90%, with HBV recurrence rates below 5% using contemporary HBIG + NUC prophylaxis protocols. For HBV-related HCC within Milan criteria, liver transplantation offers a 5-year recurrence-free survival of 70–80%. These outcomes are consistent with — and in some high-volume Indian LDLT centres, superior to — published outcomes from North American and European transplant registries.